Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
Holding NVAX?
Track your performance easily
NVAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.53 - $23.86
Previous Close$12.93
Volume5.72M
Average Volume (3M)7.03M
Market Cap
$2.07B
Enterprise Value$1.25B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$233.25M
Price to Earnings (P/E)―
Beta2.76
Next Earnings
Nov 06, 2024EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding160,093,639
10 Day Avg. Volume6,183,475
30 Day Avg. Volume7,034,980
Standard Deviation0.51
R-Squared0.04
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-4.79
Price to Sales (P/S)2.69
Price to Cash Flow (P/CF)1.70
P/FCF Ratio1.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda-19.05
Forecast
1Y Price Target
$18.25Price Target Upside45.30% Upside
Rating ConsensusHold
Number of Analyst Covering5
Novavax News
Bulls Say, Bears Say
Bulls Say
Cost ManagementRecalibration of cost structure has resulted in OpEx reduction of 34% vs. 2023 and maintaining OpEx FY24 guide of $700-$750M, with plans to initiate further reductions.
Distribution And PartnershipsRetail pharmacy contracts finalized with major chains, regional grocers, merchants, buying groups, and independent chains — a total of 17k+ locations vs. FY23.
Regulatory ApprovalsGlobal regulatory approvals for the updated JN.1 COVID vaccine rollout are anticipated over the coming weeks, aligning with early flu vaccine rollout timelines.
Bears Say
GuidanceDownward revised FY24 guidance, which was lowered to reflect management's decision to exclude future APAs from guidance; these result in FY25-26E revenue estimates to be lowered.
Market OutlookThe outlook for the COVID-19 vaccine market in later years remains murky and the rate at which sales might grow remains increasingly uncertain.
SalesManagement lowered FY24 vaccine sales guidance again now to $275-$375M, largely due to unwinding commercial sales activity in Europe.
---
Ownership Overview
14.90% Insiders
12.80% Mutual Funds
29.27% Other Institutional Investors
43.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $3.53 and its highest was $23.86 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 08, 2024. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.67 by -$0.68.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -$0.9.
How many shares outstanding does Novavax have?
Novavax has 160,093,640 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $0.99 in its last earnings report, missing expectations of $1.67. Following the earnings report the stock price went up 9.057%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 33M.
---
Novavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.25 (45.30% Upside)
$18.25 (45.30% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 430.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $409.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.93%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVAX Company Deck
---
NVAX Earnings Call
Q2 2024
0:00 / 0:00
---
NVAX Stock 12 Month Forecast
Average Price Target
$18.25
▲(45.30% Upside)
Technical Analysis
Best Analysts Covering NVAX
1 Year
1 Year Success Rate
20/35 ratings generated profit
1 Year Average Return
+163.00%
reiterated a buy rating 4 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +163.00% per trade.
---